Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective upped by HC Wainwright from $7.00 to $56.00 in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Piper Sandler raised their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $9.83 on Wednesday. The business’s 50 day moving average price is $0.84 and its 200-day moving average price is $0.82. Karyopharm Therapeutics has a fifty-two week low of $7.61 and a fifty-two week high of $25.50. The company has a market cap of $1.24 billion, a P/E ratio of -9.64 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million. As a group, equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its holdings in Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the period. GSA Capital Partners LLP grew its position in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after buying an additional 543,556 shares during the period. Marshall Wace LLP raised its holdings in shares of Karyopharm Therapeutics by 15.3% in the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares in the last quarter. Finally, Shay Capital LLC bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at about $116,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).